BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1230-1234

  Kote Jarai, Z ^a   Leongamornlert, D ^a   Saunders, E ^a   Tymrakiewicz, M ^a   Castro, E ^a   Mahmud, N ^a   Guy, M ^a   Edwards, S ^a,e   O'Brien, L ^a   Sawyer, E ^a   Hall, A ^a   Wilkinson, R ^a   Dadaev, T ^a   Goh, C ^a   Easton, D ^b   Goldgar, D ^c   Eeles, R ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

BRCA2 gene; cancer risk; mutation screening; prostate cancer

Indexed keywords

BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; GENE DELETION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GROUPS BY AGE; HIGH THROUGHPUT MULTIPLEX FLUORESCENCE HETERODUPLEX DETECTION SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONSET AGE; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GENE; UNITED KINGDOM;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; GENES, BRCA2; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 80053956117     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.383     Document Type: Article

References (26)

1. Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, Ostrander EA (2007) Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 13: 839-843 (Pubitemid 46340357)
2. Anderson DE, Badzioch MD (1992) Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 84: 1114-1117
3. Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91: 1580-1590 (Pubitemid 39486366)
4. Edwards SM, Dearnaley DP, Ardern-Jones A, Hamoudi RA, Easton DF, Ford D, Shearer R, Dowe A, Eeles RA (1997) No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer 76: 992-1000 (Pubitemid 27434654)
5. Edwards SM, Dunsmuir WD, Gillett CE, Lakhani SR, Corbishley C, Young M, Kirby RS, Dearnaley DP, Dowe A, Ardern-Jones A, Kelly J, Spurr N, Barnes DM, Eeles RA (1998) Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Int J Cancer 78: 1-7 (Pubitemid 28391665)
6. Edwards SM, Eeles RA (2004) Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 129C: 65-73 (Pubitemid 38989133)
7. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA, Oncology UGPCSCaBSo (2010a) Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103: 918-924
8. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA, Oncology UGPCSCaBSo (2010b) Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103: 918-924
9. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12 (Pubitemid 36056838)
10. Eeles RA, Dearnaley DP, Ardern-Jones A, Shearer RJ, Easton DF, Ford D, Edwards S, Dowe A (1997) Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 79(Suppl 1): 8-14
11. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592 (Pubitemid 46359643)
12. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134
13. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695 (Pubitemid 24087847)
14. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K (2010) Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16: 2115-2121
15. Hamel N, Kotar K, Foulkes WD (2003) Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 4: 7
16. Kote-Jarai Z, Eeles RA (1999) BRCA1, BRCA2 and their possible function in DNA damage response. Br J Cancer 81: 1099-1102
17. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C, Group HBCS (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99: 371-374
18. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW (2002) Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 20: 82-88 (Pubitemid 34522545)
19. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjörd JE, Jonsson E (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75: 758-761 (Pubitemid 27451978)
20. Thiessen EU (1974) Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 34: 1102-1107
21. Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68: 410-419 (Pubitemid 32147810)
22. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365 (Pubitemid 35154140)
23. Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL, Bolton D (2011) Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 4: 1002-1010
24. Tulinius H, Egilsson V, Olafsdóttir GH, Sigvaldason H (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 305: 855-857
25. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182 (Pubitemid 34161138)
26. Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ, kConFab Investigators (2008) Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 14: 2953-2961